2H-Naphth[1,2-b]-1,4-oxazin-9-ol,3,4,4a,5,6,10b-hexahydro-, hydrochloride (1:1), (4aR,10bR)- (858517-21-2)

Identification
Name:	2H-Naphth[1,2-b]-1,4-oxazin-9-ol,3,4,4a,5,6,10b-hexahydro-, hydrochloride (1:1), (4aR,10bR)-
Synonyms:	2H-Naphth[1,2-b]-1,4-oxazin-9-ol,3,4,4a,5,6,10b-hexahydro-, hydrochloride, (4aR,10bR)- (9CI)
CAS:	858517-21-2
Molecular Formula:	C12H15 N O2 . Cl H
Molecular Weight:	0
Molecular Structure:
Properties
Usage:	A dopamine agonist. This compound has been used as a precursor for the PET radiotracer, 11C-(+)-4-Propyl-3,4,4a,5,6,10b-hexahydro-2H-naphtho[1,2-b][1,4]oxazin-9-ol
Safety Data

Other Product

2H-Naphth[1,2-b]-1,4-oxazin-9-ol,3,4,4a,5,6,10b-hexahydro-4-propyl-, hydrochloride (1:1), (4aR,10bR)-
2H,5H-[1]Benzopyrano[4,3-b]-1,4-oxazin-9-ol,3,4,4a,10b-tetrahydro-4-propyl-, hydrochloride (1:1), (4aR,10bR)-
2H,5H-[1]Benzopyrano[4,3-b]-1,4-oxazin-9-ol,3,4,4a,10b-tetrahydro-4-propyl-, hydrochloride (1:1), (4aR,10bR)-rel-
2H,5H-[1]Benzopyrano[4,3-b]-1,4-oxazin-9-ol,3,4,4a,10b-tetrahydro-4-propyl-, (4aR,10bR)-
2H,5H-[1]Benzopyrano[4,3-b]-1,4-oxazin-9-ol,3,4,4a,10b-tetrahydro-4-propyl-, (4aR,10bR)-rel-
2H-Naphth[1,2-b]-1,4-oxazin-9-ol,3,4,4a,5,6,10b-hexahydro-4-propyl-, (4aR,10bR)-
1-[(4aR,10bR)-2,3,4a,5,6,10b-Hexahydro-9-[[tris(1-methylethyl)silyl]oxy]-4H-naphth[1,2-b]-1,4-oxazin-4-yl]ethanone
6H-Dibenzo[b,d]pyran-6-one,1,2,3,4,4a,10b-hexahydro-4a-hydroxy-9-methoxy-4,4,10b-trimethyl-8-(1-methylethyl)-,(4aR,10bR)-
2H-[1]Benzopyrano[3,4-b]pyridin-9-ol,1,3,4,4a,5,10b-hexahydro-4-propyl-, hydrochloride (1:1), (4aR,10bS)-rel-
2H-[1]Benzopyrano[3,4-b]pyridin-9-ol,1,3,4,4a,5,10b-hexahydro-4-propyl-, (4aR,10bS)-rel-
2H-[1]Benzopyrano[3,4-b]pyridin-9-ol,1,3,4,4a,5,10b-hexahydro-4-propyl-, (4aR,10bS)-rel-(-)-
2H-[1]Benzopyrano[3,4-b]pyridin-9-ol,1,3,4,4a,5,10b-hexahydro-4-propyl-, (4aR,10bS)-rel-(+)-
(2S,4aR,4bS,6aS,10aS,10bR)-4a,6a-dimethyl-1,2,3,4,4a,4b,5,6,6a,7,10,10a,10b,11-tetradecahydronaphtho[2',1':4,5]indeno[1,2-c]pyrazol-2-ol
2H-Naphth[1,2-b]-1,4-oxazine,3,4,4a,5,6,10b-hexahydro-4-propyl-, (4aR,10bR)-rel- (9CI)
b-D-Glucopyranoside,(1R,2S,4aR,4bR,6aS,7R,8R,10aR,10bR,12aR)-1-[(b-D-glucopyranosyloxy)methyl]octadecahydro-7-hydroxy-8-(hydroxymethyl)-8-[(3Z)-5-hydroxy-4-methyl-3-pentenyl]-1,4a,10a,10b-tetramethyl-2-chrysenyl(9CI)
(4aR,10bS)-4-propyl-1,3,4,4a,5,10b-hexahydro-2H-chromeno[3,4-b]pyridin-7-ol hydrochloride (1:1)
Oxireno[1',5']cyclopenta[1',2':5,6]naphth[2,1-c]oxepin-2,8(2aH,3bH)-dione,4-(acetyloxy)-1-(3-furanyl)-1,4,5,5a,6,10a,10b,11,12,12a-decahydro-3b,6,6,10a,12a-pentamethyl-,(1S,2aS,3aR,3bS,4R,5aR,10aR,10bR,12aS)-
b-D-Glucopyranoside,(1R,2S,4aR,4bR,6aS,7R,8R,10aR,10bR,12aR)-1-[(b-D-glucopyranosyloxy)methyl]octadecahydro-7-hydroxy-8-(hydroxymethyl)-1,4a,10a,10b-tetramethyl-8-(4-methyl-3-pentenyl)-2-chrysenyl2-O-b-D-glucopyranosyl- (9CI)
b-D-Glucopyranoside,(1R,2S,4aR,4bR,6'S,6aR,7R,8S,10aR,10bR,12aS)-7-[(b-D-glucopyranosyloxy)methyl]-6'-[(1S)-2-(b-D-glucopyranosyloxy)-1-methylethyl]octadecahydro-1-hydroxy-4a,4b,7,10a-tetramethylspiro[chrysene-2(1H),3'(4'H)-[2H]pyran]-8-yl2-O-b-D-glucopyranosyl- (9CI)
b-D-Glucopyranoside,(1R,2S,4aR,4bR,6'S,6aR,7R,8S,10aR,10bR,12aS)-7-[(b-D-glucopyranosyloxy)methyl]-6'-[(1S)-2-(b-D-glucopyranosyloxy)-1-methylethyl]octadecahydro-1-hydroxy-4a,4b,7,10a-tetramethylspiro[chrysene-2(1H),3'(4'H)-[2H]pyran]-8-yl2-O-b-D-xylopyranosyl- (9CI)